A wooden comb on a folded linen towel beside a small sage dish, on a sage linen tablecloth
A wooden comb on a folded linen towel beside a small sage dish, on a sage linen tablecloth

Does Ozempic, Wegovy or Zepbound cause hair loss?

It's on the labels, with smaller numbers than you might expect

November 17, 2026 · 4 min read
Updated November 15, 2026
Text it

Checkin shares general health information from FDA labels and published studies. It isn't medical advice, so check with your prescriber about your medicine. Questions about this? Text Checkin, it's free.

The short answer: Yes, hair loss is listed: in studies it was reported in 3.3% of people on Wegovy 2.4 mg and 4 to 5% on Zepbound, compared with about 1% on placebo. The labels say it was associated with weight reduction and was reported more often in women.

If you've noticed more hair in the brush since starting a GLP-1, you aren't imagining it, and you aren't the only one. Hair loss is written into several of these medicines' labels. Here are the numbers the labels give, who reported it more, and what to do if you notice it.

1.Is hair loss a side effect of GLP-1 medicines?

For three of them, the label gives a rate from placebo-controlled studies:

Hair loss in each label's placebo-controlled studies
Medicine (dose)PlaceboMedicine
Wegovy shot (2.4 mg)1%3.3%
Zepbound (5, 10, 15 mg)1%5%, 4%, 5%
Foundayo (5.5, 9, 17.2 mg)2%4%, 4%, 5%

These come from different studies in different people, so compare each row with its own placebo, not with the other rows. Sources: Wegovy, Zepbound and Foundayo labels, section 6.1.

Ozempic and Mounjaro are different. Their labels list alopecia (the medical word for hair loss) among reports that came in after approval (Ozempic and Mounjaro labels, section 6.2). Those reports come from a population of uncertain size, so the labels say it isn't always possible to reliably estimate how often it happens. That means there is no percentage to give for them.

2.Why does it happen?

The Wegovy, Zepbound and Foundayo labels each say the same thing: hair loss in people taking the medicine was "associated with weight reduction." That's as far as the labels go. They don't describe how it happens, and they don't say how long it lasts.

“Hair loss adverse reactions in WEGOVY injection-treated patients were associated with weight reduction. In a pool of studies 2, 3, and 4, hair loss was reported in 3.3% of patients treated with WEGOVY 2.4 mg (4% female, 0.9% male) and in 1% of patients treated with placebo (2% female, 0 male).”
What the label saysWegovy prescribing information, section 6.1

3.Who is more likely to notice it?

In every label that breaks it down, women reported hair loss more often than men, on the medicine and on placebo:

Hair loss by sex, from each label
MedicineWomenMenPlacebo (women, men)
Wegovy 2.4 mg4%0.9%2%, 0
Zepbound7.1%0.5%1.3%, 0%
Foundayo7%0.9%3%, 0.7%

The Wegovy label also reports a separate set of trials that included the 7.2 mg dose. In those trials, hair loss was reported in 5.8% of people on 7.2 mg (8.4% female, 0.2% male), 3.3% on 2.4 mg and 1.0% on placebo. That's a different group of studies from the table above, so the two sets of numbers shouldn't be mixed.

4.Does it make people stop treatment?

  • Zepbound: "No ZEPBOUND-treated patients and one placebo-treated patient discontinued study treatment due to hair loss" (label, section 6.1).
  • Wegovy 7.2 mg trials: in the 7.2 mg group, 1 event led to stopping treatment for good, 1 to a temporary pause and 5 to a lower dose. None of these happened in the 2.4 mg or placebo groups.

Those were decisions made with the study doctors. Whether anything about your treatment should change is your prescriber's call.

5.Does it happen in teens?

The Wegovy label reports it. In a pediatric trial, hair loss was reported in 4% of patients on Wegovy 2.4 mg and in no patients on placebo (label, section 6.1).

6.What can I do if I notice it?

  • Tell your prescriber. The Ozempic Medication Guide says to talk to your healthcare provider about any side effect that bothers you or does not go away. Hair loss counts. It helps to say when you first noticed it.
  • Ask about your eating, too. A 2025 advisory from four nutrition and obesity medicine societies emphasizes getting enough protein during GLP-1 treatment (advisory). That advice is about nutrition in general. It isn't a treatment for hair loss, but it's a fair thing to raise with your clinician or a dietitian.
  • Don't change your dose on your own. Your prescriber decides whether anything should change.

How Checkin helps with side effects

Checkin is a free AI companion for GLP-1s that you text. For this part of life on a GLP-1, it does three things:

  • Text how you feel, any time

    Plain answers from the FDA label, with a picture when it helps.

  • It checks in two days after your shot

    When many side effects show up, so you're not sorting it out alone.

  • Warning signs get a straight answer

    If something sounds serious, it tells you to call your doctor or 911 right away.

Questions people ask

How common is hair loss on Wegovy?

In Wegovy's weight-reduction studies, 3.3% of people on 2.4 mg reported it, compared with 1% on placebo.

Is hair loss more common on Zepbound or Wegovy?

The labels report 4 to 5% on Zepbound and 3.3% on Wegovy 2.4 mg, but these come from different studies, so they can't be compared head to head.

Does Ozempic cause hair loss?

Ozempic's label lists alopecia among reports received after approval, which can't give a reliable rate. Tell your prescriber if you notice it.

Should I stop my medicine if my hair is thinning?

Don't change anything on your own. Tell your prescriber; they decide whether anything should change.

Sources

  1. DailyMed: Wegovy (semaglutide) prescribing information, section 6.1
  2. DailyMed: Zepbound (tirzepatide) prescribing information, section 6.1
  3. DailyMed: Foundayo (orforglipron) prescribing information, section 6.1
  4. DailyMed: Ozempic (semaglutide) prescribing information, section 6.2, and Medication Guide
  5. DailyMed: Mounjaro (tirzepatide) prescribing information, section 6.2
  6. Nutritional priorities to support GLP-1 therapy for obesity: joint advisory from ACLM, ASN, OMA and TOS (Am J Clin Nutr 2025;122(1):344-367)

Published November 17, 2026. General information, not medical, legal or insurance advice. Check with your prescriber, pharmacist or plan.

The Checkin team writes these guides from FDA labels and published studies, and lists a source for every claim. Read more about Checkin, or text it free.

Related guides